FDA has issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for some cancer pharmaceuticals. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renewing ($60), and Sponsored account members only. Visit the site and log in/register to read.The post FDA clears a way for dramatic reduction in anima…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.